tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: Global Blood Therapeutics (GBT), Rocket Pharmaceuticals (RCKT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Global Blood Therapeutics (GBTResearch Report) and Rocket Pharmaceuticals (RCKTResearch Report) with bullish sentiments.

Global Blood Therapeutics (GBT)

In a report issued on May 5, Raju Prasad from William Blair maintained a Buy rating on Global Blood Therapeutics. The company’s shares closed last Friday at $26.87, close to its 52-week low of $24.61.

According to TipRanks.com, Prasad has 0 stars on 0-5 stars ranking scale with an average return of -8.4% and a 36.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Selecta Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $60.08 average price target, a 107.5% upside from current levels. In a report issued on April 28, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $75.00 price target.

See the top stocks recommended by analysts >>

Rocket Pharmaceuticals (RCKT)

In a report issued on May 6, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $30.00. The company’s shares closed last Friday at $9.45, close to its 52-week low of $9.29.

According to TipRanks.com, Dolezal ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -20.9% and a 19.2% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Larimar Therapeutics, and CymaBay Therapeutics.

Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $58.50, which is a 474.1% upside from current levels. In a report issued on May 5, William Blair also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GBT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More